Steven Bair, MD
Assistant Professor, Medicine-Hematology

Photo
Medical School:
  • MD, Case Western Reserve University School of Medicine (2014)
Undergraduate School:
  • BA/BS, Seattle Pacific University (WA) (2007)
Internship:
  • Hospital of the University of Pennsylvania (2015)
Residency:
  • Hospital of the University of Pennsylvania, Internal Medicine (2017)
Fellowships:
  • University of Pennsylvania Program, Hematology and Oncology (2020)
Languages: English
Department: Medicine-Hematology

Professional Titles

  • Assistant Professor

Recognition & Awards

  • Jane Alavi Award for Excellence, Abramson Cancer Center (2018)
  • Award in Cardiology, Myron F. Kanye & Lawrence J. Lantern (2014)

Research Interests

My research interests revolve around the use of “big data” (i.e., EMR-based phenotyping as well as molecular characterization of disease) to improve outcomes in patients with lymphoma and, more generally, to spur advances in precision medicine.

Publications

  • Svoboda J, Bair SM, Landsburg DJ, Dwivedy Nasta S, Nagle SJ, Barta SK, Khan N, Filicko-O'Hara J, Gaballa S, Strelec L, Chong E, Mitnick S, Waite TS, King C, Ballard H, Youngman M, Gerson J, Plastaras JP, Maity A, Bogusz AM, Hung SS, Nakamura H, Nejati R, Steidl C, Lim M, Ruella M, Schuster SJ. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica. 2021 Jun 1;106(6):1705-1713. PubMed PMID: 32414850
  • Carreau NA, Armand P, Merryman RW, Advani RH, Spinner MA, Herrera AF, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Nathan S, Karmali R, Torka P, David K, Lansigan F, Persky D, Godfrey J, Chavez JC, Xia Y, Diefenbach C. Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Br J Haematol. 2020 Oct;191(1):44-51. PubMed PMID: 32430944
  • Svoboda J, Bair SM, Landsburg DJ, Nasta SD, Nagle SJ, Barta SK, Khan N, Filicko-O'Hara J, Gaballa S, Strelec L, Chong E, Mitnick S, Waite TS, King C, Ballard H, Youngman M, Gerson J, Plastaras JP, Maity A, Bogusz AM, Hung SS, Nakamura H, Nejati R, Steidl C, Lim M, Ruella M, Schuster SJ. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica. 2020 May 15. [Epub ahead of print] PubMed PMID: 32414850
  • Merryman RW, Carreau NA, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David KA, Wei C, Lansigan F, Emery L, Persky D, Smith SM, Godfrey J, Chavez J, Cohen JB, Troxel AB, Diefenbach C, Armand P. Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. Oncologist. 2020 Jun;25(6):e993-e997. PubMed PMID: 32275786
  • Bair SM, Brandstadter JD, Ayers EC, Stadtmauer EA. Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. Cancer. 2020 Jan 1;126(9):1837-1855. PubMed PMID: 32073653
  • Carreau NA, Pail O, Armand P, Merryman R, Advani RH, Spinner MA, Herrera A, Chen R, Tomassetti S, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta S, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Godfrey J, Chavez J, Xia Y, Troxel AB, Diefenbach C. Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Oncologist. 2020 Oct;25(10):878-885. PubMed PMID: 32720734
View All (6 Total) View Less

Professional Memberships

  • American Society of Hematology, Member
  • American Society of Clinical Oncology, Member
  • American Medical Association, Member
  • American Medical Informatics Association, Member

Practice Locations

UCHealth Hematology Clinic - Anschutz Medical Campus
1665 Aurora Ct
2nd Floor, Anschutz Cancer Pavilion
Aurora, CO 80045
720-848-0300

UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

Hospital Affiliation
  • University of Colorado Hospital
Center Affiliations

Specialty Information

Specialties
  • Internal Medicine, Board Certification (2017, 2017)
  • Hematology, Board Certification (2020, 2020)
Conditions & Treatments
  • Cancers - Lymphoma
  • Cancers
  • Cancers - Leukemia (Adult Chronic)
Clinical Interests
My clinical interests revolve around the care of patients with all types of lymphoproliferative disorders, including chronic lymphocytic leukemia (CLL), indolent B-cell lymphoma, aggressive B-cell lymphoma, as well as other types of lymphoma.

Care Philosophy
I am keen to provide the best clinical care possible for patients with all of types of lymphoma. I believe that it is imperative to understand each patient and their disease to the greatest extent possible in order to provide the right treatment for the right person at the right time.

General Information

Medical Schools:
  • MD, Case Western Reserve University School of Medicine (2014)
Undergraduate Schools:
  • BA/BS, Seattle Pacific University (WA) (2007)
Internships:
  • Hospital of the University of Pennsylvania (2015)
Residency Programs:
  • Hospital of the University of Pennsylvania, Internal Medicine (2017)
Fellowships:
  • University of Pennsylvania Program, Hematology and Oncology (2020)
Languages: English
Department: Medicine-Hematology
Contact Us
CU Anschutz
Fitzsimons Building

13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile
;